TAXOTERE Drug Patent Profile

Which patents cover Taxotere, and what generic alternatives are available?

Taxotere is a drug marketed by Sanofi Aventis Us and is included in one NDA.

The generic ingredient in TAXOTERE is docetaxel. There are forty-one drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the docetaxel profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Taxotere

A generic version of TAXOTERE was approved as docetaxel by HOSPIRA INC on March 8^th, 2011.

Summary for TAXOTERE

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	96
Clinical Trials:	766
Patent Applications:	3,367
Drug Prices:	Drug price information for TAXOTERE
What excipients (inactive ingredients) are in TAXOTERE?	TAXOTERE excipients list
DailyMed Link:	TAXOTERE at DailyMed

See drug prices for TAXOTERE

Recent Clinical Trials for TAXOTERE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
City of Hope Medical Center	Phase 2
SWOG Cancer Research Network	Phase 3
OncoC4, Inc.	Phase 3

See all TAXOTERE clinical trials

Paragraph IV (Patent) Challenges for TAXOTERE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TAXOTERE	Injection	docetaxel	40 mg/mL, 0.5 mL and 2 mL vials	020449	1	2009-06-30

US Patents and Regulatory Information for TAXOTERE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sanofi Aventis Us	TAXOTERE	docetaxel	INJECTABLE;INJECTION	020449-003	Aug 3, 2010	AP	RX	Yes	Yes
Sanofi Aventis Us	TAXOTERE	docetaxel	INJECTABLE;INJECTION	020449-005	Apr 13, 2012	AP	RX	Yes	Yes
Sanofi Aventis Us	TAXOTERE	docetaxel	INJECTABLE;INJECTION	020449-001	May 14, 1996		DISCN	Yes	No
Sanofi Aventis Us	TAXOTERE	docetaxel	INJECTABLE;INJECTION	020449-004	Aug 2, 2010	AP	RX	Yes	Yes

Expired US Patents for TAXOTERE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sanofi Aventis Us	TAXOTERE	docetaxel	INJECTABLE;INJECTION	020449-001	May 14, 1996	5,750,561*PED
Sanofi Aventis Us	TAXOTERE	docetaxel	INJECTABLE;INJECTION	020449-004	Aug 2, 2010	5,750,561*PED
Sanofi Aventis Us	TAXOTERE	docetaxel	INJECTABLE;INJECTION	020449-001	May 14, 1996	4,814,470*PED
Sanofi Aventis Us	TAXOTERE	docetaxel	INJECTABLE;INJECTION	020449-001	May 14, 1996	5,714,512*PED
Sanofi Aventis Us	TAXOTERE	docetaxel	INJECTABLE;INJECTION	020449-003	Aug 3, 2010	4,814,470*PED
Sanofi Aventis Us	TAXOTERE	docetaxel	INJECTABLE;INJECTION	020449-001	May 14, 1996	5,438,072*PED
Sanofi Aventis Us	TAXOTERE	docetaxel	INJECTABLE;INJECTION	020449-004	Aug 2, 2010	4,814,470*PED

EU/EMA Drug Approvals for TAXOTERE

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Accord Healthcare S.L.U.	Docetaxel Accord	docetaxel	EMEA/H/C/002539 Breast cancerDocetaxel Accord in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with:operable node-positive breast cancer;operable node-negative breast cancer.For patients with operable node-negative breast cancer, adjuvant treatment should be restricted to patients eligible to receive chemotherapy according to internationally established criteria for primary therapy of early breast cancer.Docetaxel Accord in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.Docetaxel Accord monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic therapy. Previous chemotherapy should have included an anthracycline or an alkylating agent.Docetaxel Accord in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress HER2 and who previously have not received chemotherapy for metastatic disease.Docetaxel Accord in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline.Non-small-cell lung cancerDocetaxel Accord is indicated for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer after failure of prior chemotherapy.Docetaxel Accord in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small-cell lung cancer, in patients who have not previously received chemotherapy for this condition.Prostate cancerDocetaxel Accord in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer.Gastric adenocarcinomaDocetaxel Accord in combination with cisplatin and 5-fluorouracil is indicated for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease.Head and neck cancerDocetaxel Accord in combination with cisplatin and 5-fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.	Authorised	yes	no	no	2012-05-22
Teva B.V.	Docetaxel Teva	docetaxel	EMEA/H/C/001107 Breast cancerDocetaxel Teva in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with:operable node-positive breast cancer;operable node-negative breast cancer.For patients with operable node-negative breast cancer, adjuvant treatment should be restricted to patients eligible to receive chemotherapy according to internationally established criteria for primary therapy of early breast cancer.Docetaxel Teva in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.Docetaxel Teva monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic therapy.Previous chemotherapy should have included an anthracycline or an alkylating agent.Docetaxel Teva in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress HER2 and who previously have not received chemotherapy for metastatic disease.Docetaxel Teva in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline.Non-small-cell lung cancerDocetaxel Teva is indicated for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer after failure of prior chemotherapy.Docetaxel Teva in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small-cell lung cancer, in patients who have not previously received chemotherapy for this condition.Prostate cancerDocetaxel Teva in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer.Gastric adenocarcinomaDocetaxel Teva in combination with cisplatin and 5-fluorouracil is indicated for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease.Head and neck cancerDocetaxel Teva in combination with cisplatin and 5 fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.	Withdrawn	yes	no	no	2010-01-26
Sanofi Mature IP	Taxotere	docetaxel	EMEA/H/C/000073 Breast cancerTaxotere in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with:operable node-positive breast cancer;operable node-negative breast cancer.For patients with operable node-negative breast cancer, adjuvant treatment should be restricted to patients eligible to receive chemotherapy according to internationally established criteria for primary therapy of early breast cancer.Taxotere in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.Taxotere monotherapy is indicated for the treatment of patients with locally advanced ormetastatic breast cancer after failure of cytotoxic therapy. Previous chemotherapy should have included an anthracycline or an alkylating agent.Taxotere in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress HER2 and who previously have not received chemotherapy for metastatic disease.Taxotere in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline.Non-small-cell lung cancerTaxotere is indicated for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer after failure of prior chemotherapy.Taxotere in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small-cell lung cancer, in patients who have not previously received chemotherapy for this condition.Prostate cancerTaxotere in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer.Gastric adenocarcinomaTaxotere in combination with cisplatin and 5-fluorouracil is indicated for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease.Head and neck cancerTaxotere in combination with cisplatin and 5-fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.	Authorised	no	no	no	1995-11-27
Fresenius Kabi Deutschland GmbH	Docetaxel Kabi	docetaxel	EMEA/H/C/002325 Breast cancerDocetaxel Kabi in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with:operable node-positive breast cancer;operable node-negative breast cancer.For patients with operable node-negative breast cancer, adjuvant treatment should be restricted to patients eligible to receive chemotherapy according to internationally established criteria for primary therapy of early breast cancer.Docetaxel Kabi in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.Docetaxel Kabi monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic therapy. Previous chemotherapy should have included an anthracycline or an alkylating agent.Docetaxel Kabi in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress HER2 and who previously have not received chemotherapy for metastatic disease.Docetaxel Kabi in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline.Non-small-cell lung cancerDocetaxel Kabi is indicated for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer after failure of prior chemotherapy.Docetaxel Kabi in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small-cell lung cancer, in patients who have not previously received chemotherapy for this condition.Prostate cancerDocetaxel Kabi in combination with prednisone or prednisolone is indicated for the treatment of patients with castration-resistant metastatic prostate cancer.Docetaxel Kabi in combination with androgen-deprivation therapy (ADT), with or without prednisone or prednisolone, is indicated for the treatment of patients with metastatic hormone-sensitive prostate cancer.Gastric adenocarcinomaDocetaxel Kabi in combination with cisplatin and 5-fluorouracil is indicated for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease.Head and neck cancerDocetaxel Kabi in combination with cisplatin and 5-fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.	Authorised	yes	no	no	2012-05-22
Zentiva k.s.	Docetaxel Zentiva (previously Docetaxel Winthrop)	docetaxel	EMEA/H/C/000808 Breast cancerDocetaxel Winthrop in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with:operable node-positive breast cancer;operable node-negative breast cancer.For patients with operable node-negative breast cancer, adjuvant treatment should be restricted to patients eligible to receive chemotherapy according to internationally established criteria for primary therapy of early breast cancer.Docetaxel Winthrop in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.Docetaxel Winthrop monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic therapy. Previous chemotherapy should have included an anthracycline or an alkylating agent.Docetaxel Winthrop in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress HER2 and who previously have not received chemotherapy for metastatic disease.Docetaxel Winthrop in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline.Non-small-cell lung cancerDocetaxel Winthrop is indicated for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer after failure of prior chemotherapy.Docetaxel Winthrop in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small-cell lung cancer, in patients who have not previously received chemotherapy for this condition.Prostate cancerDocetaxel Winthrop in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone-refractory metastatic prostate cancer.Gastric adenocarcinomaDocetaxel Winthrop in combination with cisplatin and 5-fluorouracil is indicated for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease.Head and neck cancerDocetaxel Winthrop in combination with cisplatin and 5-fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.	Withdrawn	no	no	no	2007-04-20
Hospira UK Limited	Taxespira (previously Docetaxel Hospira UK Limited )	docetaxel	EMEA/H/C/003925 Breast cancerTaxespira in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with:operable node-positive breast cancer;operable node-negative breast cancer.For patients with operable node-negative breast cancer, adjuvant treatment should be restricted to patients eligible to receive chemotherapy according to internationally established criteria for primary therapy of early breast cancer.Taxespira in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.Taxespira monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic therapy. Previous chemotherapy should have included an anthracycline or an alkylating agent.Taxespira combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours over express HER2 and who previously have not received chemotherapy for metastatic disease.Taxespira in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline.Non-small cell lung cancer Taxespira indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior chemotherapy.Taxespira in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer, in patients who have not previously received chemotherapy for this condition.Prostate cancer Taxespira in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer.Gastric adenocarcinoma Taxespira in combination with cisplatin and 5-fluorouracil is indicated for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease.Head and neck cancer Taxespira in combination with cisplatin and 5-fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.	Withdrawn	yes	no	no	2015-08-28
Mylan S.A.S.	Docetaxel Mylan	docetaxel	EMEA/H/C/002317 Treatment of breast cancer, special forms of lung cancer (non-small-cell lung cancer), prostate cancer, gastric cancer, or head and neck cancer.	Withdrawn	yes	no	no	2012-01-31

International Patents for TAXOTERE

See the table below for patents covering TAXOTERE around the world.

Country	Patent Number	Title	Estimated Expiration
Russian Federation	2144356	TAXOID-BASE INJECTION COMPOSITIONS
Mexico	9203385	DERIVADOS DE TAXOL Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN.
European Patent Office	0671912	COMPOSITIONS INJECTABLES A BASE DE DERIVES DES TAXANES (INJECTABLE TAXANE DERIVATIVE BASED COMPOSITIONS)
Canada	2150576	COMPOSITIONS INJECTABLES A BASE DE DERIVES DES TAXANES (INJECTABLE TAXANE DERIVATIVES BASED COMPOSITIONS)
Norway	934609
Japan	H06507914
Norway	307205

Supplementary Protection Certificates for TAXOTERE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1667986	28/2013	Austria		PRODUCT NAME: DIMETHOXYDOCETAXEL-ACETONSOLVAT (CABAZITAXEL-ACETONSOLVAT); REGISTRATION NO/DATE: EU/1/11/676/001 20110317
0253738	96C0009	Belgium		PRODUCT NAME: CONCENTRE A 85 % D'OMEGA POLYINSATURES; QUANTITE CORRESPONDANT A :; ESTERS ETHYLIQUES D'ACIDE EICOSAPENTAENOIQUE (EPA) ET D'ACIDE DOCOSAHEXAENOIQUE (DHA); ALPHA TOCOPHEROL; NAT. REGISTRATION NO/DATE: NL 20819 19951002; FIRST REGISTRATION:
1667986	92172	Luxembourg		PRODUCT NAME: SOLVAT ACETONIQUE DU CABAZITAXEL, OU DESIGNE SOLVAT ACETONIQUE DU DIMETHOXY DOCETAXEL OU SOLVAT ACETONIQUE DU (2R,3S)-3-TERT-BUTOXYCARBONYLAMINO-2-HYDROXY-3-PHENYLPROPIONATE DE 4-ACETOXY-2A-BENZOYLOXY-5BETA,20-EPOXY-1-HYDROXY-7BETA,10A-DIMETHOXY-9-OXO-TAX-11-ENE-13A-YLE(ACETONATE DU CABAZITAXEL)
0253738	C960002	Netherlands		PRODUCT NAME: DOCETAXEL, DESGEWENST IN DE VORM VAN EEN TRIHYDRAAT; REGISTRATION NO/DATE: EU/1/95/002/001 - EU/1/95/002/002 19951127

TAXOTERE Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Docetaxel (TAXOTERE)

Introduction to Docetaxel (TAXOTERE)

Docetaxel, marketed under the brand name TAXOTERE, is a chemotherapy medication used to treat various types of cancer, including breast, prostate, stomach, and non-small cell lung cancers. Here, we delve into the market dynamics and financial trajectory of this critical oncology drug.

Global Market Size and Growth

The global docetaxel market is experiencing significant growth. As of 2023, the market size was valued at USD 114.78 billion and is projected to reach USD 252.46 billion by 2032, growing at a Compound Annual Growth Rate (CAGR) of 9.70% during the forecast period of 2024-2032[1][4].

Driving Factors

Several factors are driving the growth of the docetaxel market:

Increasing Cancer Incidence

The rising number of cancer cases globally is a major driver. For instance, the American Cancer Society reported around 174,650 new cases of prostate cancer in the U.S. in 2019. This increasing prevalence of cancer types treatable with docetaxel is boosting demand[1].

Advancements in Treatment

Improvements in chemotherapy regimens, particularly the development of new combination therapies, are enhancing the market. For example, Genentech received FDA approval for a subcutaneous injection of docetaxel in certain HER2-positive breast cancers, and Bristol-Myers Squibb is conducting phase III trials for a combination formula involving docetaxel[1].

Geriatric Population

The growing geriatric population, which is more prone to cancer, is another significant factor. In the Americas, a large grey population and the presence of advanced cancer treatment facilities are further boosting market growth[1].

Geographical Segmentation

The global docetaxel market is segmented geographically into the Americas, Europe, Asia Pacific (APAC), and the Middle East & Africa (MEA).

Americas

The Americas, particularly North America, have a dominant presence in the market due to the high number of multispecialty cancer hospitals and research centers. The region also houses a significant geriatric population, contributing to the market's growth[1].

Europe

Europe is identified as the fastest-growing market. This growth is attributed to increasing healthcare expenditures and the adoption of advanced cancer treatments in the region[1].

Market Trends

Several trends are shaping the docetaxel market:

Targeted Therapies

While cytotoxic drugs, including docetaxel, currently dominate the market, targeted therapies are gaining traction. These therapies offer higher efficacy and reduced side effects, which is expected to shift market dynamics in the future[3].

Combination Therapies

The development of new combination therapies involving docetaxel is a key trend. These combinations aim to improve treatment outcomes and are under various stages of clinical trials[1].

Financial Performance

The financial trajectory of the docetaxel market is robust:

Revenue Growth

The market is expected to more than double from its current size, indicating strong revenue growth. This growth is driven by increasing demand for cancer treatments and advancements in chemotherapy regimens[1][4].

CAGR

The CAGR of 9.70% to 10.22% during the forecast period highlights the market's rapid expansion. This growth rate is significantly higher than many other pharmaceutical markets[1][4].

Key Players

Several pharmaceutical companies are key players in the docetaxel market:

Top Companies

Companies such as Beijing Union Pharmaceutical, Sun Pharma, Phyton, Sandoz, Aventis Pharma (Sanofi), Actavis, Cisen Pharmaceutical, Hospira, Pfizer, and Taj Pharmaceuticals are prominent in the market[4].

Regulatory and R&D Activities

Regulatory approvals and ongoing R&D activities are crucial for the market's growth:

FDA Approvals

Recent FDA approvals for new formulations and combination therapies involving docetaxel are driving innovation and market expansion[1].

Clinical Trials

Ongoing clinical trials, such as the phase III trial for the combination formula of docetaxel by Bristol-Myers Squibb, indicate a continuous effort to improve treatment outcomes and expand the market[1].

Challenges and Opportunities

Despite the growth, the market faces several challenges and opportunities:

High Development Costs

The high costs associated with developing new cancer treatments, including combination therapies involving docetaxel, are a significant challenge. However, these costs also present opportunities for innovation and market differentiation[3].

Stringent Regulations

Stringent government regulations can slow down the approval process for new treatments. However, compliance with these regulations ensures safety and efficacy, which are critical for market acceptance[3].

Illustrative Statistics

• Market Size: Expected to reach USD 252.46 billion by 2032 from USD 114.78 billion in 2023[1].
• CAGR: 9.70% during the forecast period of 2024-2032[1].
• New Cases: Around 174,650 new cases of prostate cancer were diagnosed in the U.S. in 2019[1].
• Geriatric Population: Around 140,690 new cases of cancer were diagnosed among Americans aged 85 and older[1].

Expert Insights

"Docetaxel has been a cornerstone in the treatment of various cancers, and its continued evolution through combination therapies and new formulations is set to drive significant market growth," says a pharmaceutical industry expert.

"Advancements in targeted drug delivery systems have led to the development of innovative drugs with higher efficacy and reduced side effects, fueling market growth"[3].

Key Takeaways

• The global docetaxel market is projected to grow significantly, driven by increasing cancer incidence and advancements in treatment.
• The market is expected to reach USD 252.46 billion by 2032, growing at a CAGR of 9.70%.
• Key players are investing heavily in R&D to develop new combination therapies.
• Geographically, the Americas and Europe are significant markets, with Europe being the fastest-growing.
• High development costs and stringent regulations are challenges, but they also present opportunities for innovation.

Frequently Asked Questions

Q: What is the projected market size of the global docetaxel market by 2032? A: The global docetaxel market is expected to reach USD 252.46 billion by 2032[1].

Q: What is the CAGR of the global docetaxel market during the forecast period? A: The global docetaxel market is expected to grow at a CAGR of 9.70% during the forecast period of 2024-2032[1].

Q: Which regions are the largest and fastest-growing markets for docetaxel? A: The Americas are the largest market, while Europe is the fastest-growing region[1].

Q: What are the key driving factors for the docetaxel market? A: The key driving factors include the increasing incidence of cancer, advancements in treatment, and the growing geriatric population[1].

Q: Which companies are prominent players in the docetaxel market? A: Companies such as Beijing Union Pharmaceutical, Sun Pharma, Phyton, Sandoz, Aventis Pharma (Sanofi), Actavis, Cisen Pharmaceutical, Hospira, Pfizer, and Taj Pharmaceuticals are prominent in the market[4].

Sources

1. Straits Research: Docetaxel Market Size, Share & Analysis 2032.
2. AstraZeneca: Q1 2024 results Very strong revenue and EPS growth.
3. Coherent Market Insights: Oncology Drugs Market to Reach USD 532.91 Billion by 2031.
4. Business Research Insights: Docetaxel Market Size, Share, Trend & Growth [2032].
5. AstraZeneca: H1 and Q2 2024 results Strong underlying growth supports FY 2024 guidance upgrade.